Mass Tort Advertising Campaign
Roundup, Bayer/Monsanto's widely used glyphosate-based herbicide, sits at the center of one of the most significant mass tort litigations in recent memory. Plaintiffs allege that chronic glyphosate exposure caused Non-Hodgkin Lymphoma — a serious blood cancer — and that the manufacturer failed to adequately warn users of that risk. With intake still open and a settlement posture established in the litigation, this tort represents a mature, actively monetizable advertising opportunity for plaintiff firms ready to scale acquisition.
For law firm marketing directors and plaintiff attorneys evaluating paid social, Roundup checks the core boxes: a recognizable brand name, a severe and well-defined injury, a sympathetic claimant profile that spans agricultural workers to everyday homeowners, and a defendant with the resources to resolve claims. MTAA has the creative infrastructure and audience architecture to move qualified claimants through your intake funnel efficiently.
Bayer inherited the Roundup liability when it acquired Monsanto, and the litigation has since produced a settlement framework that gives plaintiff firms a defined resolution pathway. The central allegation — that occupational and regular consumer exposure to glyphosate causes Non-Hodgkin Lymphoma — has been tested extensively in court, generating a body of case law and public awareness that meaningfully lowers the educational barrier in advertising. Juries and the broader public are already familiar with the Roundup name and the cancer link, which translates directly into higher ad engagement and lower friction at intake.
Intake remains open, meaning firms are still actively building inventories of qualifying claimants. The injury at issue — Non-Hodgkin Lymphoma — is a defined, diagnosable condition, which keeps disqualification rates manageable when campaigns are built around the right qualification signals. The combination of settlement posture and continued intake openness makes this a tort where advertising investment can be deployed with a clear line of sight to case resolution.
Roundup advertising on Meta performs best when it leans into the occupational identity of the core claimant — the farmer who sprayed for decades, the landscaper who used it weekly, the homeowner who treated their yard every season for years. MTAA builds creative that speaks directly to that lived experience, connecting the familiar Roundup brand name to the Non-Hodgkin Lymphoma diagnosis in plain, empathetic language. Because glyphosate and Roundup already carry significant public awareness, we can move faster through the education phase of the funnel and focus creative energy on driving the recognition moment: I used that product, I have that diagnosis, I should find out if I have a case. The Agent Orange litigation provides a useful creative parallel — a herbicide tied to a specific cancer in a population with strong occupational identity — and informs how we frame exposure history and injury in ad copy without overstating outcomes.
Audience architecture for this tort layers occupational signals (agriculture, landscaping, groundskeeping, property maintenance) with geographic targeting toward rural and suburban markets where Roundup use was heaviest. Lookalike modeling built from your existing claimant data accelerates scale once the initial funnel is validated. Intake fit is strong: the qualification criteria are binary enough — years of use, NHL diagnosis — that a well-scripted intake team or automated pre-screen can sort leads quickly, keeping cost-per-signed metrics predictable as you grow volume.
Mass Tort Ad Agency runs Roundup (Glyphosate) campaigns on the same transparent model as every tort: actual Meta ad spend at cost plus a flat 15% management fee, a one-time $1,000 setup fee per tort, and $100 per signed retainer for CloudIntake qualification. No per-case markups, no lead resale, and the firm owns its ad account, pixel, creative, and claimant data.
We build, run, and qualify Roundup (Glyphosate) claimant-acquisition campaigns end to end. Book a call and we'll walk you through the creative, audience, and intake plan.
Book a strategy call